Reference : Le pimecrolimus topique (Elidel).
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/11076
Le pimecrolimus topique (Elidel).
French
[en] Medication of the month. Topical pimecrolimus (Elidel).
Quatresooz, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Fumal, I. [Centre Hospitalier Régional de Huy > > > > Dermatologie > >]
Pierard, Claudine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Pierard, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
2003
Revue Médicale de Liège
58
3
168-71
Yes (verified by ORBi)
National
0370-629X
2566-1566
Belgium
[en] Administration, Cutaneous ; Calcineurin/antagonists & inhibitors ; Dermatitis, Atopic/drug therapy ; Dermatologic Agents/pharmacology/therapeutic use ; Humans ; Peptidylprolyl Isomerase/antagonists & inhibitors ; Tacrolimus/analogs & derivatives/pharmacology/therapeutic use
[en] Pimecrolimus inhibits some specific steps of the Th1 and Th2 immune reactions. It belongs to the class of ascomycin macrolactams. The topical drug formulation targets cutaneous inflammation, more particularly lymphocytes and mast cells without impairing systemic immunosurveillance. Topical applications are indicated for treating atopic dermatitis. In this indication, it represents an alternative or an adjuvant drug to topical corticosteroids. The treatment of other dermatoses could also benefit from pimecrolimus.
http://hdl.handle.net/2268/11076

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
PIMECROLIMUS ELIDEL.pdfNo commentaryPublisher postprint506.21 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.